(Q30868078)

27 June 2017

1 reference

title

Ziprasidone for schizophrenia and severe mental illness (English)

1 reference

27 June 2017

1 reference

A Bagnall

1

1 reference

27 June 2017

R A Lewis

series ordinal

2

1 reference

27 June 2017

M L Leitner

series ordinal

3

1 reference

27 June 2017

J Kleijnen

series ordinal

4

1 reference

27 June 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Cochrane Database of Systematic Reviews

27 June 2017

2000

0 references

published in

1 reference

27 June 2017

issue

2

1 reference

27 June 2017

4

0 references

page(s)

CD001945

1 reference

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

27 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Atypical neuroleptics in children and adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Olanzapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Risperidone versus typical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

Quetiapine for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001945

10.1002/14651858.CD001945

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference